Related Experiment Video
Updated: Dec 28, 2025
07:34
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
3.0K
Cannabinoid agonists possibly mediate interaction between cholinergic and cannabinoid systems in regulating
Diva de Aguiar Magalhães1, Stefany Guimarães Sousa1, Antônio Kleiton de Sousa2
1Laboratory of Experimental Physiopharmacology (LAFFEX), Federal University of Piauí, Parnaíba, PI, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.
Medical Hypotheses
|February 23, 2020
Summary
This study explores how the body
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal condition.
- IBD pathogenesis involves genetic, environmental, and immune factors.
- Endogenous systems like the cholinergic and endocannabinoid systems are crucial for intestinal health.
Purpose of the Study:
- To investigate the interaction between the muscarinic and cannabinoid systems in controlling intestinal inflammation.
- To explore the role of endogenous cannabinoids in mediating the anti-inflammatory effects of the cholinergic system in IBD.
Main Methods:
- Review of existing literature on IBD, cholinergic system, and endocannabinoid system.
- Analysis of proposed mechanisms of interaction between muscarinic receptors and cannabinoid signaling in the gut.
Main Results:
- The cholinergic system exhibits anti-inflammatory properties relevant to IBD.
- Endocannabinoids are vital for restoring bowel function during inflammation.
- Evidence suggests an interconnection between cholinergic and cannabinoid systems in various tissues.
Conclusions:
- The muscarinic system's control of intestinal inflammation may be mediated by endogenous cannabinoids.
- Activation of muscarinic receptors likely stimulates endogenous cannabinoid production in the intestine.
- This interaction represents a potential therapeutic target for Inflammatory Bowel Disease.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
607
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
607
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.2K
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
556
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
556
01:29Inflammatory Bowel Disease IV: Pharmacological Management
386
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
386
01:30Parasympathetic Signaling
2.9K
Parasympathetic signaling plays a crucial role in regulating various physiological processes. It involves the release of acetylcholine (ACh) by parasympathetic neurons, which can have localized and short-lived effects. The majority of ACh released is rapidly inactivated at the synapse by the enzyme acetylcholinesterase (AChE), which hydrolyzes Ach into choline and acetate. Additionally, the tissue cholinesterase deactivates any ACh diffusing into the surrounding tissues.
The effects of...
The effects of...
2.9K
01:28Cholinergic Antagonists: Pharmacological Actions
1.6K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.6K